drugset / Trial / NCT00805480

Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis

NCT00805480

Phase 2 Completed 130 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.

Timeline

Start
2008-12
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Secukinumab Monoclonal antibody 3 mg/kg Intravenous
Subject Secukinumab Monoclonal antibody 10 mg/kg Intravenous

Indications